Table 2.
Estimates of actual and potential lives saved from the deployment of CCP in Italy, year 2020.
| (a) Hospitalized Patients | |||
|---|---|---|---|
| Relative Risk Reduction (%) 1 | Untreated Mortality (%) 2 |
Lives Saved (n) | |
| Real-Life | Theoretical 3 | ||
| 13 | 32.4 | 146 | 10,107 |
| 23 | 32.4 | 258 | 17,882 |
| 44 | 32.4 | 493 | 34,209 |
| (b) Outpatients | |||
|
Population Treated
with CCP (%) 4 |
Hospitalization Reduction (%) 5 | Hospitalization Avoided (n) |
Lives Saved
(n) |
| 15 | 30 | 10,798 | 3499 |
| 75 | 30 | 53,992 | 17,493 |
| 15 | 54 | 19,437 | 6298 |
| 75 | 54 | 97,185 | 31,488 |
| 15 | 80 | 28,796 | 9330 |
| 75 | 80 | 143,978 | 46,649 |
1 The 13% value comes from reference no. 6; the 23% value comes from reference no. 13 and the 44% value comes from reference no. 15. 2 The 32.4% value comes from reference no. 18. 3 Calculated if 100% inpatients were transfused with CCP. 4 Percentage of use of 15% was estimated from the actual use of monoclonal antibodies during the pandemic, which was given to patients at high risk for hospitalization. The 75% estimate assumes a major national effort to deploy outpatient plasma. 5 The 30% value comes from reference no. 22; the 54% value comes from reference no. 21 and the 80% value comes from reference no. 7.